Inspire Medical Systems, Inc. Announces Countrywide Reimbursement in France
July 23 2024 - 8:00AM
Inspire Medical Systems, Inc. (NYSE: INSP) (Inspire), a medical
technology company focused on the development and commercialization
of innovative, minimally invasive solutions for patients with
obstructive sleep apnea (OSA), announced today the publication of
the reimbursement of Inspire therapy in France.
“We are thrilled to offer our clinically proven treatment option
for moderate to severe OSA to patients and physicians in France,”
said Tim Herbert, Chairman and Chief Executive Officer of Inspire.
“Inspire therapy is backed by a strong body of evidence and years
of clinical experience demonstrating the safety and efficacy of our
therapy.”
Inspire therapy received European Conformity Marking for
commercialization in Europe in 2010. Since that time, the company’s
approach has been to secure reimbursement in targeted countries
prior to commencing commercialization efforts. Inspire has already
established reimbursement in many key European countries, and the
addition of full reimbursement in France expands the market
opportunity as France is the second largest OSA market in Europe.
The approval in France provides reimbursement consistent with other
European and global markets.
“Thanks to the reimbursement of Inspire therapy by the French
Social Security, sleep physicians now have a new therapeutic option
for patients with untreated OSA,” said Andreas Henke, Executive
Vice President, Managing Director Europe.
About Inspire Medical Systems
Inspire is a medical technology company focused on the
development and commercialization of innovative, minimally invasive
solutions for patients with obstructive sleep apnea. Inspire’s
proprietary Inspire therapy is the first and only FDA-approved
neurostimulation technology that provides a safe and effective
treatment for moderate to severe obstructive sleep apnea.
For additional information about Inspire, please visit
www.inspiresleep.com or www.inspiresleep.fr.
Forward Looking Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995. All statements other than statements of historical facts are
forward-looking statements, including, without limitation, those
regarding our expectations to commercialize Inspire therapy in
France. Forward-looking statements involve inherent risks and
uncertainties, and important factors could cause actual results to
differ materially from those anticipated, including the factors
identified under the captions “Risk Factors” and “Management's
Discussion and Analysis of Financial Condition and Results of
Operations” in our Annual Report on Form 10-K for the fiscal year
ended December 31, 2023 filed with the SEC, and as such factors may
be updated from time to time in our other filings with the SEC,
which are accessible on the SEC’s website at www.sec.gov and the
Investors page of our website at www.inspiresleep.com.
Forward-looking statements speak only as of the date they are made,
and we undertake no obligation to update them in light of new
information or future events.
Investor and Media ContactEzgi YagciVice
President, Investor
Relationsezgiyagci@inspiresleep.com617-549-2443
Inspire Medical Systems (NYSE:INSP)
Historical Stock Chart
From Jul 2024 to Aug 2024
Inspire Medical Systems (NYSE:INSP)
Historical Stock Chart
From Aug 2023 to Aug 2024